Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

BACKGROUND AND AIMS: Vedolizumab is an anti-α4β7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the u...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Crohns Colitis
Auteurs principaux: Veny, Marisol, Garrido-Trigo, Alba, Corraliza, Ana M, Masamunt, Maria C, Bassolas-Molina, Helena, Esteller, Miriam, Arroyes, Montserrat, Tristán, Eva, Fernández-Clotet, Agnès, Ordás, Ingrid, Ricart, Elena, Esteve, Maria, Panés, Julian, Salas, Azucena
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7944518/
https://ncbi.nlm.nih.gov/pubmed/32926095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa178
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires